Abstract:Emerging evidence suggests that GSK3β, a redox-sensitive transducer downstream of insulin signaling, acts as a convergent point for myriad pathways implicated in kidney injury, repair, and regeneration. However, its role in diabetic kidney disease remains controversial. In cultured glomerular podocytes, exposure to a milieu of type 2 diabetes elicited prominent signs of podocyte injury and degeneration, marked by loss of homeostatic marker proteins like synaptopodin, actin cytoskeleton disruption, oxidative stress and apoptosis, and stress-induced premature senescence, as shown by increased staining for senescence-associated β-galactosidase activity, amplified formation of γH2AX foci, and elevated expression of mediators of senescence signaling, like p21 and p16INK4A. These degenerative changes coincided with GSK3β hyperactivity, as evidenced by GSK3β overexpression and reduced inhibitory phosphorylation of GSK3β, and were averted by tideglusib, a highly-selective small molecule inhibitor of GSK3β. In agreement, post-hoc analysis of a publicly-available glomerular transcriptomics dataset from patients with type 2 diabetic nephropathy revealed that the curated diabetic nephropathy-related gene set was enriched in high GSK3β expression group. Mechanistically, GSK3β-modulated nuclear factor Nrf2 signaling is involved in diabetic podocytopathy, because GSK3β knockdown reinforced Nrf2 antioxidant response and suppressed oxidative stress, resulting in an improvement in podocyte injury and senescence. Conversely, ectopic expression of the constitutively active mutant of GSK3β impaired Nrf2 antioxidant response and augmented oxidative stress, culminating in an exacerbated diabetic podocyte injury and senescence. Moreover, IRS-1 was found to be a cognate substrate of GSK3β for phosphorylation at IRS-1S332, which negatively regulates IRS-1 activity. GSK3β hyperactivity promoted IRS-1 phosphorylation, denoting a desensitized insulin signaling. Consistently, in vivo in db/db mice with diabetic nephropathy, GSK3β was hyperactive in glomerular podocytes, associated with IRS-1 hyperphosphorylation, impaired Nrf2 response and premature senescence. Our finding suggests that GSK3β is likely a novel therapeutic target for treating type 2 diabetic glomerular injury.

GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease

GSK3: A potential target and pending issues for treatment of Alzheimer's disease

Targeting glycogen synthase kinase-3 β for Alzheimer's disease: Recent advances and future Prospects

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer's Disease

Glycogen synthase kinase-3: A potential target for diabetes

Targeting Glycogen Synthase Kinase-3Β for Alzheimer's Disease: Recent Advances and Future Prospects

Studies of glycogen synthase kinase-3 inhibitors

GSK-3 in Neurodegenerative Diseases

Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases

The Redox-Sensitive GSK3β is a Key Regulator of Glomerular Podocyte Injury in Type 2 Diabetic Kidney Disease

The Key Roles of GSK-3β in Regulating Mitochondrial Activity

Advances in Study of Glycogen Synthase Kinase-3β and Its Inhibitors

Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer's Disease Treatment

Advances in the Therapeutic Potential of Inhibitors Targeting Glycogen Synthase Kinase 3 in Inflammatory Diseases

Glycogen synthase kinase-3 regulates production of amyloid-β peptides and tau phosphorylation in diabetic rat brain.

Pharmacological Targeting of GSK3β Confers Protection Against Podocytopathy and Proteinuria by Desensitizing Mitochondrial Permeability Transition

Development of Inhibitors Targeting Glycogen Synthase Kinase-3Β for Human Diseases: Strategies to Improve Selectivity.

GSK3 in Alzheimer's Disease: Mind the Isoforms

Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer's therapy

GSK3 is a Central Player in Retinal Degenerative Diseases but a Challenging Therapeutic Target